ZS Pharma is committed to advancing patient care by developing new therapeutic compounds to treat serious conditions related to kidney and liver diseases. Its lead investigational therapy, ZS-9, is a novel agent for the treatment of hyperkalemia, a potentially life threatening condition characterized by abnormally high levels of potassium in the blood. ZS-9 is in late stage clinical trials to demonstrate its ability to safely, effectively, and rapidly remove excess potassium.
Keep up to date with the latest ZS Pharma News and UpdatesSign Up
ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for HyperkalemiaDownload PDF
ZS Pharma Announces Positive Results from the Extended Treatment Phase of its Phase 3 Trial of ZS-9 in Patients with HyperkalemiaDownload PDF
ZS Pharma to Present at J.P. Morgan Healthcare ConferenceDownload PDF